AbbVie Inc.
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Contingent Consideration Payments by Year
Contingent Consideration Payments — Operating Cash Flow Portion ($M) ($M)
AbbVie Contingent Consideration Payments: $2,865M in FY2025, up 43.6% from a year earlier.
Latest, FY2025
2,865
Period ended Dec 31, 2025
Change on a year earlier
+43.6%
1,995 in FY2024
History
5 years
Since FY2021
Sources
3
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-20) ↗
Reported in Form 10-Q / 10-K Consolidated Statements of Cash Flows.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Contingent Consideration Payments — Operating Cash Flow Portion ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2,865 | +43.6% | Form 10-K (filed 2026-02-20) ↗ |
| FY2024 | Dec 31, 2024 | 1,995 | +129.3% | Form 10-K (filed 2026-02-20) ↗ |
| FY2023 | Dec 31, 2023 | 870 | +430.5% | Form 10-K (filed 2026-02-20) ↗ |
| FY2022 | Dec 31, 2022 | 164 | +80.2% | Form 10-K (filed 2025-02-14) ↗ |
| FY2021 | Dec 31, 2021 | 91 | – | Form 10-K (filed 2024-02-20) ↗ |
Cite this data
StockData. (2026). AbbVie Contingent Consideration Payments ($M), annual FY2021–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/cc-payments-op
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.